Gefitinib: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Michal Harel, Joel L. Sussman

@@ Line 12: / Line 12: @@
 {| class="wikitable" border="1" width="40%" style="text-align:center"
 |-
-!  colspan="6" align="center"| EGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID:16609030</ref><ref>PMID:17482782</ref>
+!  colspan="4" align="center"| EGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID:16609030</ref><ref>PMID:17482782</ref><ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref>
 |-
 ! Parameter
 ! [[Erlotinib]] (Tarceva)
 ! [[Gefitinib]] (Iressa)
+! Lapatinib (Tykerb)
 |-
 ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
 ! 2.0
 ! 5.4
+! 8.3
 |-
 ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
 ! 69.6
 ! 130
 |-
 ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
 ! 99
 ! 59
+! 29-49
 |-
 ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
 ! 93
 ! 90
+! 99
 |-
 ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
 ! 9.4
 ! 26.9
+! 29
 |-
 ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
 ! 20577
 ! 3850
+! 11040
 |-
 ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
 ! 2
 ! 23
+! 12
 |-
 ! Typical Dosage (mg)
 ! 150
 ! 250
+! 50
 |-
 ! Metabolism
 ! Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1)
 ! Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1, CYP1A2)
+! Hepatic (CYP3A4)
 |}